Ramoplanin
未知生产厂商
Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.
Ramoplanin is the first in a new class of antimicrobials to reach clinical trials. It is a glycolipodepsipeptide produced by the fermentation of Actinoplanes spp.. Ramoplanin blocks bacterial cell wall biosynthesis by interfering with peptidoglycan production. Ramoplanin inhibits the N-acetylglucosaminyltransferase-catalysed conversion of lipid intermediate I to lipid intermediate II, a step that occurs before the transglycosylation and transpeptidation reactions. Ramoplanin’s mechanism of action is distinct from that of glycopeptides. Unlike glycopeptides, ramoplanin does not complex with the D-Ala–D-Ala sequence of cell wall precursors.
适用于治疗胃肠道感染性疾病，尤其对艰难梭状杆菌引起的腹泻有较好的治疗作用。
